Ipatasertib plus paclitaxel in the first-line setting does not confer a progression-free survival (PFS) benefit to patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), according to a study presented at SABCS 2020.
The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score ≤25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.
While breast cancer survivors of childbearing age are less likely to get pregnant than the general population, most of them who do become pregnant deliver healthy babies without detrimental outcomes on their long-term survival, according to a large meta-analysis presented at the SABCS 2020 Congress.
Omitting radiotherapy after breast-conserving surgery in older patients with hormone receptor (HR)-positive breast cancer who were also receiving appropriate systemic therapy did not impact overall survival (OS) at 10 years, even though the rate of local recurrence was higher than those who had radiotherapy, according to the PRIME* II study presented at SABCS 2020.
Behavioural interventions are effective in mitigating depressive symptoms in young survivors of breast cancer, according to a study presented at SABCS 2020. In particular, mindfulness meditation also improves other outcomes related to well-being such as fatigue and sleep disturbance.